Coya Therapeutics (NASDAQ:COYA – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Coya Therapeutics to post earnings of ($0.32) per share for the quarter.
Coya Therapeutics Stock Up 0.2 %
NASDAQ:COYA opened at $6.49 on Friday. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.69. The stock has a market capitalization of $108.43 million, a PE ratio of -9.98 and a beta of 0.31. The stock’s 50-day moving average price is $6.28 and its 200-day moving average price is $6.47.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research note on Monday, March 10th.
About Coya Therapeutics
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Stories
- Five stocks we like better than Coya Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to buy stock: A step-by-step guide for beginners
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What to Know About Investing in Penny Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
